The drug rituximab has been shown to be of benefit when used with chemotherapy in adult patients with B cell lymphoma. There is some experience with using rituximab in combination with standard chemotherapy to treat children and adolescents, but not enough to know yet whether it is helpful. It is possible that the effectiveness of rituximab will be different than it is in adults. There are differences in the types of B-Non Hodgkin Lymphoma (B-NHL) and mature B-cell Leukemia (B-AL) between children and adults. The goal of this study for children and adolescents with high risk B-Cell Non-Hodgkins Lymphoma or mature B-cell leukemia (B-ALL) is to see if using rituximab in combination with standard chemotherapy versus standard chemotherapy alone will result in improved treatment outcome (example, a lower chance of the disease to come back [relapse]). Participants with B-NHL and B-AL will be assigned to different groups based on the extent of their individual disease, and then will receive one of two treatment arms specific to each group. Participants will be randomly assigned with equal probability to one of the two treatment arms.
ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients
081-12Principal Investigator: Conducted at:
Miller Children‘s Hospital Long BeachCurrently enrolling additional patients: